A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and Blood draw in HIV Infections and Pneumococcal Infections, sponsored by Pfizer. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-10.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in HIV Infections by Pfizer — none open to participants now, none under way, none of them phase 3. HIV Infections · Pfizer.
Among the 65 studies in HIV Infections by Pfizer, this one is the 6th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 64th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 65 studies in HIV Infections by Pfizer is open now. The open studies under HIV Infections, anywhere →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 331 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 160 across the 28 interventional studies, 476 across the 1 observational. Of the 65 that completed or were terminated, 5 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 65 studies in HIV Infections by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older who have been previously immunized with at least one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS). All subjects will receive 3 doses of 13vPnC, with each study vaccine dose given approximately 6 months apart.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Temporary Delay Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent pneumococcal conjugate vaccine · Procedure: Blood draw
Three doses of 13vPnC given 6 months apart.
Also known as: 13vPnC
Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: 1 month post-dose 2, 1 month post-dose 3
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means (GMs) were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.
Time frame: 1 month post-dose 2, 1 month post-dose 3
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 1 and post-dose 2 blood draws.
Time frame: 1 month post-dose 1, 1 month post-dose 2
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 3 of 13vPnC Relative to 1 Month After Dose 2 of 13vPnC
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.
Time frame: 1 month post-dose 2, 1 month post-dose 3
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Dose 2 of 13vPnC Relative to 1 Month After Dose 1 of 13vPnC
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.
Time frame: 1 month post-dose 1, 1 month post-dose 2
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC
GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: 1 month post-dose 2, 1 month post-dose 3
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After Dose 1 of 13vPnC to 1 Month After Dose 2 of 13vPnC
GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 1 to 1 month post-dose 2 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: 1 month post-dose 1, 1 month post-dose 2
Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.5 to 10.0 cm); Severe (greater than \[\>\] 10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).
Time frame: Within 14 days post-dose 1
Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).
Time frame: Within 14 days post-dose 2
Percentage of Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).
Time frame: Within 14 days post-dose 3
Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1
Specific systemic events (fever greater than or equal to \[\>=\]38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours \[hrs\]); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs). Report of fever \>40 degrees C after 13vPnC Dose 1 was confirmed as data entry error.
Time frame: Within 14 days post-dose 1
Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2
Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).
Time frame: Within 14 days post-dose 2
Percentage of Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3
Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).
Time frame: Within 14 days post-dose 3
| Milestone | 13vPnC |
|---|---|
| Started | 331 |
| Vaccinated dose 1 | 329 |
| Vaccinated dose 2 | 300 |
| Vaccinated dose 3 | 279 |
| Completed dose 3 1-month blood draw | 277 |
| Completed | 271 |
| Not completed | 60 |
| Withdrew: Withdrawal by subject | 22 |
| Withdrew: Lost to follow-up | 14 |
| Withdrew: Failed to return | 9 |
| Withdrew: Protocol violation | 7 |
| Withdrew: Adverse event | 5 |
| Withdrew: Physician decision | 2 |
| Withdrew: Other | 1 |
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| fold rise | 13vPnC |
|---|---|
| Serotype 1 | 0.94 (0.88 to 1.01) |
| Serotype 3 | 1.01 (0.95 to 1.08) |
| Serotype 4 | 1.01 (0.94 to 1.08) |
| Serotype 5 | 0.99 (0.94 to 1.05) |
| Serotype 6A | 1.19 (1.11 to 1.27) |
| Serotype 6B | 1.21 (1.13 to 1.31) |
| Serotype 7F | 1.07 (1.00 to 1.14) |
| Serotype 9V | 1.08 (1.02 to 1.15) |
| Serotype 14 | 1.08 (0.99 to 1.17) |
| Serotype 18C | 1.09 (1.02 to 1.16) |
| Serotype 19A | 1.03 (0.98 to 1.09) |
| Serotype 19F | 1.17 (1.08 to 1.27) |
| Serotype 23F | 1.25 (1.15 to 1.37) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means (GMs) were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.
| microgram per milliliter (mcg/mL) | 13vPnC |
|---|---|
| Serotype 1: Dose 2 | 2.31 (1.97 to 2.72) |
| Serotype 1: Dose 3 | 2.18 (1.88 to 2.54) |
| Serotype 3: Dose 2 | 0.54 (0.47 to 0.62) |
| Serotype 3: Dose 3 | 0.55 (0.47 to 0.63) |
| Serotype 4: Dose 2 | 1.62 (1.41 to 1.87) |
| Serotype 4: Dose 3 | 1.63 (1.42 to 1.88) |
| Serotype 5: Dose 2 | 3.26 (2.79 to 3.80) |
| Serotype 5: Dose 3 | 3.23 (2.78 to 3.75) |
| Serotype 6A: Dose 2 | 3.86 (3.20 to 4.66) |
| Serotype 6A: Dose 3 | 4.60 (3.85 to 5.50) |
| Serotype 6B: Dose 2 | 4.49 (3.70 to 5.46) |
| Serotype 6B: Dose 3 | 5.45 (4.53 to 6.57) |
| Serotype 7F: Dose 2 | 3.40 (2.95 to 3.92) |
| Serotype 7F: Dose 3 | 3.62 (3.17 to 4.14) |
| Serotype 9V: Dose 2 | 2.95 (2.56 to 3.41) |
| Serotype 9V: Dose 3 | 3.20 (2.79 to 3.66) |
| Serotype 14: Dose 2 | 7.57 (6.27 to 9.15) |
| Serotype 14: Dose 3 | 8.16 (6.87 to 9.69) |
| Serotype 18C: Dose 2 | 2.75 (2.33 to 3.24) |
| Serotype 18C: Dose 3 | 2.99 (2.56 to 3.50) |
| Serotype 19A: Dose 2 | 7.57 (6.54 to 8.76) |
| Serotype 19A: Dose 3 | 7.80 (6.82 to 8.93) |
| Serotype 19F: Dose 2 | 5.73 (4.73 to 6.95) |
| Serotype 19F: Dose 3 | 6.70 (5.61 to 8.01) |
| Serotype 23F: Dose 2 | 3.80 (3.17 to 4.57) |
| Serotype 23F: Dose 3 | 4.77 (4.01 to 5.67) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 1 and post-dose 2 blood draws.
| mcg/mL | 13vPnC |
|---|---|
| Serotype 1: Dose 1 | 2.15 (1.80 to 2.57) |
| Serotype 1: Dose 2 | 2.36 (2.03 to 2.75) |
| Serotype 3: Dose 1 | 0.48 (0.41 to 0.56) |
| Serotype 3: Dose 2 | 0.57 (0.49 to 0.65) |
| Serotype 4: Dose 1 | 1.37 (1.15 to 1.64) |
| Serotype 4: Dose 2 | 1.64 (1.43 to 1.89) |
| Serotype 5: Dose 1 | 2.90 (2.48 to 3.40) |
| Serotype 5: Dose 2 | 3.29 (2.83 to 3.81) |
| Serotype 6A: Dose 1 | 2.80 (2.28 to 3.43) |
| Serotype 6A: Dose 2 | 3.86 (3.23 to 4.62) |
| Serotype 6B: Dose 1 | 2.90 (2.36 to 3.57) |
| Serotype 6B: Dose 2 | 4.47 (3.72 to 5.38) |
| Serotype 7F: Dose 1 | 3.45 (2.91 to 4.11) |
| Serotype 7F: Dose 2 | 3.41 (2.99 to 3.90) |
| Serotype 9V: Dose 1 | 2.63 (2.25 to 3.07) |
| Serotype 9V: Dose 2 | 2.99 (2.62 to 3.42) |
| Serotype 14: Dose 1 | 6.18 (4.97 to 7.68) |
| Serotype 14: Dose 2 | 7.60 (6.35 to 9.09) |
| Serotype 18C: Dose 1 | 2.87 (2.37 to 3.48) |
| Serotype 18C: Dose 2 | 2.68 (2.29 to 3.13) |
| Serotype 19A: Dose 1 | 6.53 (5.54 to 7.69) |
| Serotype 19A: Dose 2 | 7.63 (6.65 to 8.74) |
| Serotype 19F: Dose 1 | 2.75 (2.18 to 3.49) |
| Serotype 19F: Dose 2 | 5.70 (4.75 to 6.84) |
| Serotype 23F: Dose 1 | 2.62 (2.11 to 3.25) |
| Serotype 23F: Dose 2 | 3.82 (3.21 to 4.56) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.
| titers | 13vPnC |
|---|---|
| Serotype 1: Dose 2 | 41 (32.6 to 50.9) |
| Serotype 1: Dose 3 | 49 (40.1 to 61.0) |
| Serotype 3: Dose 2 | 44 (36.9 to 52.4) |
| Serotype 3: Dose 3 | 56 (47.5 to 66.3) |
| Serotype 4: Dose 2 | 703 (567.6 to 870.5) |
| Serotype 4: Dose 3 | 724 (585.2 to 896.6) |
| Serotype 5: Dose 2 | 67 (51.9 to 86.1) |
| Serotype 5: Dose 3 | 74 (57.6 to 94.2) |
| Serotype 6A: Dose 2 | 1780 (1392.7 to 2274.5) |
| Serotype 6A: Dose 3 | 2139 (1709.0 to 2678.3) |
| Serotype 6B: Dose 2 | 1857 (1509.8 to 2284.3) |
| Serotype 6B: Dose 3 | 2447 (2011.9 to 2977.3) |
| Serotype 7F: Dose 2 | 942 (778.6 to 1139.6) |
| Serotype 7F: Dose 3 | 1041 (846.5 to 1279.4) |
| Serotype 9V: Dose 2 | 657 (482.7 to 893.4) |
| Serotype 9V: Dose 3 | 922 (696.0 to 1221.7) |
| Serotype 14: Dose 2 | 746 (614.8 to 905.8) |
| Serotype 14: Dose 3 | 819 (684.7 to 978.8) |
| Serotype 18C: Dose 2 | 521 (383.9 to 706.2) |
| Serotype 18C: Dose 3 | 692 (516.2 to 927.7) |
| Serotype 19A: Dose 2 | 401 (340.2 to 473.0) |
| Serotype 19A: Dose 3 | 419 (358.2 to 490.5) |
| Serotype 19F: Dose 2 | 269 (202.3 to 357.3) |
| Serotype 19F: Dose 3 | 245 (184.2 to 325.8) |
| Serotype 23F: Dose 2 | 293 (217.2 to 395.0) |
| Serotype 23F: Dose 3 | 393 (295.0 to 522.7) |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for both post-dose 2 and post-dose 3 blood draws.
| titers | 13vPnC |
|---|---|
| Serotype 1: Dose 1 | 40 (32.2 to 50.2) |
| Serotype 1: Dose 2 | 40 (32.6 to 49.7) |
| Serotype 3: Dose 1 | 29 (24.0 to 34.9) |
| Serotype 3: Dose 2 | 43 (36.4 to 51.4) |
| Serotype 4: Dose 1 | 622 (478.8 to 806.9) |
| Serotype 4: Dose 2 | 695 (568.1 to 850.7) |
| Serotype 5: Dose 1 | 66 (51.2 to 85.7) |
| Serotype 5: Dose 2 | 65 (50.8 to 82.1) |
| Serotype 6A: Dose 1 | 976 (710.3 to 1342.0) |
| Serotype 6A: Dose 2 | 1687 (1317.2 to 2159.5) |
| Serotype 6B: Dose 1 | 1088 (806.0 to 1468.4) |
| Serotype 6B: Dose 2 | 1789 (1443.4 to 2216.8) |
| Serotype 7F: Dose 1 | 786 (606.6 to 1018.0) |
| Serotype 7F: Dose 2 | 927 (763.6 to 1125.2) |
| Serotype 9V: Dose 1 | 423 (300.6 to 594.1) |
| Serotype 9V: Dose 2 | 695 (518.3 to 932.0) |
| Serotype 14: Dose 1 | 640 (509.2 to 805.7) |
| Serotype 14: Dose 2 | 723 (602.4 to 867.2) |
| Serotype 18C: Dose 1 | 475 (338.5 to 665.5) |
| Serotype 18C: Dose 2 | 562 (421.7 to 748.9) |
| Serotype 19A: Dose 1 | 299 (239.7 to 372.2) |
| Serotype 19A: Dose 2 | 391 (333.2 to 458.6) |
| Serotype 19F: Dose 1 | 132 (93.6 to 185.0) |
| Serotype 19F: Dose 2 | 247 (189.3 to 322.9) |
| Serotype 23F: Dose 1 | 92 (65.6 to 127.9) |
| Serotype 23F: Dose 2 | 269 (201.3 to 360.7) |
GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 2 to 1 month post-dose 3 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| fold rise | 13vPnC |
|---|---|
| Serotype 1 | 1.2 (1.06 to 1.39) |
| Serotype 3 | 1.3 (1.13 to 1.44) |
| Serotype 4 | 1.0 (0.90 to 1.18) |
| Serotype 5 | 1.1 (0.95 to 1.28) |
| Serotype 6A | 1.2 (1.04 to 1.39) |
| Serotype 6B | 1.3 (1.16 to 1.50) |
| Serotype 7F | 1.1 (0.95 to 1.28) |
| Serotype 9V | 1.4 (1.09 to 1.81) |
| Serotype 14 | 1.1 (0.97 to 1.24) |
| Serotype 18C | 1.3 (1.10 to 1.60) |
| Serotype 19A | 1.0 (0.95 to 1.15) |
| Serotype 19F | 0.9 (0.76 to 1.09) |
| Serotype 23F | 1.3 (1.16 to 1.56) |
GMFRs for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month post-dose 1 to 1 month post-dose 2 were computed using the logarithmically transformed assay results. CI for the GMFRs were back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| fold rise | 13vPnC |
|---|---|
| Serotype 1 | 1.0 (0.84 to 1.20) |
| Serotype 3 | 1.5 (1.29 to 1.73) |
| Serotype 4 | 1.1 (0.92 to 1.36) |
| Serotype 5 | 1.0 (0.79 to 1.20) |
| Serotype 6A | 1.7 (1.39 to 2.15) |
| Serotype 6B | 1.6 (1.34 to 2.02) |
| Serotype 7F | 1.2 (0.96 to 1.45) |
| Serotype 9V | 1.6 (1.26 to 2.14) |
| Serotype 14 | 1.1 (0.98 to 1.30) |
| Serotype 18C | 1.2 (0.95 to 1.47) |
| Serotype 19A | 1.3 (1.15 to 1.50) |
| Serotype 19F | 1.9 (1.48 to 2.39) |
| Serotype 23F | 2.9 (2.29 to 3.77) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]); Moderate (5.5 to 10.0 cm); Severe (greater than \[\>\] 10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).
| percentage of participants | 13vPnC |
|---|---|
| Redness: any (n = 162) | 5.6 (2.6 to 10.3) |
| Redness: mild (n = 161) | 4.3 (1.8 to 8.8) |
| Redness: moderate (n = 158) | 1.3 (0.2 to 4.5) |
| Redness: severe (n = 157) | 0.0 (0.0 to 2.3) |
| Swelling: any (n = 162) | 6.8 (3.4 to 11.8) |
| Swelling: mild (n = 161) | 6.2 (3.0 to 11.1) |
| Swelling: moderate (n = 158) | 0.6 (0.0 to 3.5) |
| Swelling: severe (n = 158) | 0.6 (0.0 to 3.5) |
| Pain: any (n = 260) | 78.8 (73.4 to 83.6) |
| Pain: mild (n = 258) | 76.4 (70.7 to 81.4) |
| Pain: moderate (n = 173) | 18.5 (13.0 to 25.1) |
| Pain: severe (n = 158) | 1.3 (0.2 to 4.5) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).
| percentage of participants | 13vPnC |
|---|---|
| Redness: any (n = 122) | 8.2 (4.0 to 14.6) |
| Redness: mild (n = 120) | 6.7 (2.9 to 12.7) |
| Redness: moderate (n = 117) | 1.7 (0.2 to 6.0) |
| Redness: severe (n = 117) | 1.7 (0.2 to 6.0) |
| Swelling: any (n = 126) | 12.7 (7.4 to 19.8) |
| Swelling: mild (n = 125) | 12.0 (6.9 to 19.0) |
| Swelling: moderate (n = 116) | 0.9 (0.0 to 4.7) |
| Swelling: severe (n = 117) | 1.7 (0.2 to 6.0) |
| Pain: any (n = 237) | 81.4 (75.9 to 86.2) |
| Pain: mild (n = 230) | 78.7 (72.8 to 83.8) |
| Pain: moderate (n = 150) | 33.3 (25.9 to 41.5) |
| Pain: severe (n = 123) | 8.1 (4.0 to 14.4) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm); Moderate (5.5 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating).
| percentage of participants | 13vPnC |
|---|---|
| Redness: any (n = 105) | 9.5 (4.7 to 16.8) |
| Redness: mild (n = 104) | 8.7 (4.0 to 15.8) |
| Redness: moderate (n = 102) | 3.9 (1.1 to 9.7) |
| Redness: severe (n = 101) | 1.0 (0.0 to 5.4) |
| Swelling: any (n = 107) | 11.2 (5.9 to 18.8) |
| Swelling: mild (n = 106) | 8.5 (4.0 to 15.5) |
| Swelling: moderate (n = 102) | 3.9 (1.1 to 9.7) |
| Swelling: severe (n = 101) | 1.0 (0.0 to 5.4) |
| Pain: any (n = 204) | 81.9 (75.9 to 86.9) |
| Pain: mild (n = 197) | 80.2 (73.9 to 85.5) |
| Pain: moderate (n = 129) | 30.2 (22.5 to 38.9) |
| Pain: severe (n = 105) | 5.7 (2.1 to 12.0) |
Specific systemic events (fever greater than or equal to \[\>=\]38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours \[hrs\]); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs). Report of fever \>40 degrees C after 13vPnC Dose 1 was confirmed as data entry error.
| percentage of participants | 13vPnC |
|---|---|
| Fever >=38 degrees C (n = 162) | 6.2 (3.0 to 11.1) |
| Fever >=38, <38.5 degrees C (n = 160) | 3.8 (1.4 to 8.0) |
| Fever >=38.5, <39 degrees C (n = 157) | 1.3 (0.2 to 4.5) |
| Fever >=39, =<40 degrees C (n = 159) | 1.3 (0.2 to 4.5) |
| Fever >40 degrees C (n = 158) | 0.6 (0.0 to 3.5) |
| Fatigue: any (n = 235) | 60.0 (53.4 to 66.3) |
| Fatigue: mild (n = 223) | 54.3 (47.5 to 60.9) |
| Fatigue: moderate (n = 200) | 37.5 (30.8 to 44.6) |
| Fatigue: severe (n = 163) | 6.1 (3.0 to 11.0) |
| Headache: any (n = 224) | 61.6 (54.9 to 68.0) |
| Headache: mild (n = 216) | 57.4 (50.5 to 64.1) |
| Headache: moderate (n = 183) | 31.1 (24.5 to 38.4) |
| Headache: severe (n = 160) | 3.1 (1.0 to 7.1) |
| Vomiting: any (n = 164) | 11.6 (7.1 to 17.5) |
| Vomiting: mild (n = 164) | 11.6 (7.1 to 17.5) |
| Vomiting: moderate (n = 157) | 0.0 (0.0 to 2.3) |
| Vomiting: severe (n = 157) | 0.0 (0.0 to 2.3) |
| Diarrhea: any (n = 193) | 44.0 (36.9 to 51.3) |
| Diarrhea: mild (n = 191) | 40.3 (33.3 to 47.6) |
| Diarrhea: moderate (n = 166) | 12.7 (8.0 to 18.7) |
| Diarrhea: severe (n = 160) | 1.9 (0.4 to 5.4) |
| New generalized muscle pain: any (n = 234) | 65.0 (58.5 to 71.1) |
| New generalized muscle pain: mild (n = 230) | 60.4 (53.8 to 66.8) |
| New generalized muscle pain: moderate (n = 183) | 29.5 (23.0 to 36.7) |
| New generalized muscle pain: severe (n = 161) | 3.7 (1.4 to 7.9) |
| New generalized joint pain: any (n = 193) | 35.8 (29.0 to 43.0) |
| New generalized joint pain: mild (n = 185) | 29.7 (23.2 to 36.9) |
| New generalized joint pain: moderate (n = 172) | 19.2 (13.6 to 25.9) |
| New generalized joint pain: severe (n = 159) | 1.3 (0.2 to 4.5) |
| Use of medication to treat pain (n = 185) | 29.7 (23.2 to 36.9) |
| Use of medication to treat fever (n = 173) | 17.3 (12.0 to 23.8) |
Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).
| percentage of participants | 13vPnC |
|---|---|
| Fever >=38 degrees C (n = 117) | 5.1 (1.9 to 10.8) |
| Fever >=38, <38.5 degrees C (n = 116) | 4.3 (1.4 to 9.8) |
| Fever >=38.5, <39 degrees C (n = 116) | 0.9 (0.0 to 4.7) |
| Fever >=39, =<40 degrees C (n = 115) | 0.0 (0.0 to 3.2) |
| Fever >40 degrees C (n = 115) | 0.0 (0.0 to 3.2) |
| Fatigue: any (n = 188) | 63.3 (56.0 to 70.2) |
| Fatigue: mild (n = 176) | 57.4 (49.7 to 64.8) |
| Fatigue: moderate (n = 154) | 38.3 (30.6 to 46.5) |
| Fatigue: severe (n = 121) | 7.4 (3.5 to 13.7) |
| Headache: any (n = 173) | 56.1 (48.3 to 63.6) |
| Headache: mild (n = 165) | 48.5 (40.6 to 56.4) |
| Headache: moderate (n = 142) | 31.0 (23.5 to 39.3) |
| Headache: severe (n = 117) | 3.4 (0.9 to 8.5) |
| Vomiting: any (n = 120) | 7.5 (3.5 to 13.8) |
| Vomiting: mild (n = 119) | 6.7 (2.9 to 12.8) |
| Vomiting: moderate (n = 116) | 0.9 (0.0 to 4.7) |
| Vomiting: severe (n = 115) | 0.0 (0.0 to 3.2) |
| Diarrhea: any (n = 155) | 44.5 (36.5 to 52.7) |
| Diarrhea: mild (n = 147) | 39.5 (31.5 to 47.8) |
| Diarrhea: moderate (n = 130) | 15.4 (9.7 to 22.8) |
| Diarrhea: severe (n = 119) | 5.0 (1.9 to 10.7) |
| New generalized muscle pain: any (n = 199) | 71.9 (65.1 to 78.0) |
| New generalized muscle pain: mild (n = 188) | 66.0 (58.7 to 72.7) |
| New generalized muscle pain: moderate (n = 153) | 38.6 (30.8 to 46.8) |
| New generalized muscle pain: severe (n = 125) | 10.4 (5.7 to 17.1) |
| New generalized joint pain: any (n = 150) | 40.0 (32.1 to 48.3) |
| New generalized joint pain: mild (n = 144) | 34.7 (27.0 to 43.1) |
| New generalized joint pain: moderate (n = 135) | 21.5 (14.9 to 29.4) |
| New generalized joint pain: severe (n = 119) | 3.4 (0.9 to 8.4) |
| Use of medication to treat pain (n = 141) | 35.5 (27.6 to 44.0) |
| Use of medication to treat fever (n = 127) | 18.9 (12.5 to 26.8) |
Specific systemic events (fever \>=38 degrees C, fatigue, headache, vomiting, diarrhea, new generalized muscle/joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, new generalized muscle and joint pain were scaled as: Any (symptom present); Mild (no interference with activity); Moderate (some interference); Severe (prevents routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hrs); Moderate (\>2 times in 24 hrs); Severe (requires intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hrs); Moderate (4-5 loose stools 24 hrs); Severe (\>=6 loose stools in 24 hrs).
| percentage of participants | 13vPnC |
|---|---|
| Fever >=38 degrees C (n = 104) | 7.7 (3.4 to 14.6) |
| Fever >=38, <38.5 degrees C (n = 104) | 4.8 (1.6 to 10.9) |
| Fever >=38.5, <39 degrees C (n = 101) | 1.0 (0.0 to 5.4) |
| Fever >=39, =<40 degrees C (n = 101) | 2.0 (0.2 to 7.0) |
| Fever >40 degrees C (n = 101) | 0.0 (0.0 to 3.6) |
| Fatigue: any (n = 160) | 56.3 (48.2 to 64.1) |
| Fatigue: mild (n = 149) | 48.3 (40.1 to 56.6) |
| Fatigue: moderate (n = 132) | 36.4 (28.2 to 45.2) |
| Fatigue: severe (n = 105) | 5.7 (2.1 to 12.0) |
| Headache: any (n = 137) | 46.7 (38.1 to 55.4) |
| Headache: mild (n = 130) | 40.8 (32.2 to 49.7) |
| Headache: moderate (n = 118) | 24.6 (17.1 to 33.4) |
| Headache: severe (n = 103) | 4.9 (1.6 to 11.0) |
| Vomiting: any (n = 109) | 11.0 (5.8 to 18.4) |
| Vomiting: mild (n = 107) | 8.4 (3.9 to 15.4) |
| Vomiting: moderate (n = 104) | 4.8 (1.6 to 10.9) |
| Vomiting: severe (n = 101) | 0.0 (0.0 to 3.6) |
| Diarrhea: any (n = 134) | 38.8 (30.5 to 47.6) |
| Diarrhea: mild (n = 131) | 35.9 (27.7 to 44.7) |
| Diarrhea: moderate (n = 109) | 11.9 (6.5 to 19.5) |
| Diarrhea: severe (n = 103) | 1.9 (0.2 to 6.8) |
| New generalized muscle pain: any (n = 170) | 65.9 (58.2 to 73.0) |
| New generalized muscle pain: mild (n = 155) | 61.3 (53.1 to 69.0) |
| New generalized muscle pain: moderate (n = 132) | 31.1 (23.3 to 39.7) |
| New generalized muscle pain: severe (n = 110) | 10.0 (5.1 to 17.2) |
| New generalized joint pain: any (n = 129) | 31.8 (23.9 to 40.6) |
| New generalized joint pain: mild (n = 119) | 26.1 (18.4 to 34.9) |
| New generalized joint pain: moderate (n = 120) | 20.0 (13.3 to 28.3) |
| New generalized joint pain: severe (n = 106) | 5.7 (2.1 to 11.9) |
| Use of medication to treat pain (n = 122) | 32.0 (23.8 to 41.0) |
| Use of medication to treat fever (n = 118) | 25.4 (17.9 to 34.3) |
Collected over Adverse events (AEs)/serious AEs (SAEs): recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events (up to 14 days after each vaccine dose). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC (After Dose 1 and Before Dose 2) | — | 24/329 (7.3%) | 244/329 (74.2%) |
| 13vPnC (After Dose 2 and Before Dose 3) | — | 14/300 (4.7%) | 196/300 (65.3%) |
| 13vPnC (After Dose 3 and Before Dose 3 Blood Draw) | — | 4/278 (1.4%) | 169/278 (60.8%) |
| 13vPnC (After Dose 3 Blood Draw) | — | 10/329 (3%) | 30/329 (9.1%) |
| Event | 13vPnC (After Dose 1 and Before Dose 2) | 13vPnC (After Dose 2 and Before Dose 3) | 13vPnC (After Dose 3 and Before Dose 3 Blood Draw) | 13vPnC (After Dose 3 Blood Draw) |
|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 3/329 | 0/300 | 0/278 | 0/329 |
| Angina pectorisCardiac disorders | 0/329 | 2/300 | 0/278 | 0/329 |
| Non-cardiac chest painGeneral disorders | 2/329 | 0/300 | 0/278 | 0/329 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/329 | 1/300 | 0/278 | 2/329 |
| Angina unstableCardiac disorders | 0/329 | 0/300 | 1/278 | 0/329 |
| PneumoniaInfections and infestations | 0/329 | 1/300 | 1/278 | 0/329 |
| Alcohol abusePsychiatric disorders | 1/329 | 0/300 | 1/278 | 1/329 |
| Aortic aneurysmVascular disorders | 1/329 | 0/300 | 1/278 | 0/329 |
| Prinzmetal anginaCardiac disorders | 0/329 | 1/300 | 0/278 | 0/329 |
| Erosive oesophagitisGastrointestinal disorders | 0/329 | 1/300 | 0/278 | 0/329 |
| Event | 13vPnC (After Dose 1 and Before Dose 2) | 13vPnC (After Dose 2 and Before Dose 3) | 13vPnC (After Dose 3 and Before Dose 3 Blood Draw) | 13vPnC (After Dose 3 Blood Draw) |
|---|---|---|---|---|
| Pain (Any)Skin and subcutaneous tissue disorders | 205/260 | 193/237 | 167/204 | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 197/258 | 181/230 | 158/197 | — |
| New generalized muscle pain (Any)General disorders | 152/234 | 143/199 | 112/170 | — |
| New generalized muscle pain (Mild)General disorders | 139/230 | 124/188 | 95/155 | — |
| Fatigue (Any)General disorders | 141/235 | 119/188 | 90/160 | — |
| Headache (Any)General disorders | 138/224 | 97/173 | 64/137 | — |
| Headache (Mild)General disorders | 124/216 | 80/165 | 53/130 | — |
| Fatigue (Mild)General disorders | 121/223 | 101/176 | 72/149 | — |
| Diarrhea (Any)General disorders | 85/193 | 69/155 | 52/134 | — |
| Diarrhea (Mild)General disorders | 77/191 | 58/147 | 47/131 | — |
Safety population included participants who received at least 1 dose of study vaccine.
| Age Continuous(years) | 13vPnC |
|---|---|
| Mean | 47.3 ± 9.10 |
| Sex: Female, Male(Participants) | 13vPnC |
|---|---|
| Female | 66 |
| Male | 263 |
The record gives a start of Nov 2009, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine